Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis

Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis

Objectives: This network meta-analysis aimed to compare the efficacy and safety of fluoroquinolone (FQ) monotherapy, β-lactam (BL) monotherapy and β-lactam/macrolide (BL-M) combination therapy in hospitalized patients with community-acquired pneumonia (CAP). Methods: Pubmed, Embase and the Cochrane...

Full description

Bibliographic Details
Main Authors:	Lu-Yan Xu, Can-Can Wang, Xiao-Xiao Peng, Ying Jiao, Cui-Zhu Zhao, Li Zhang, Li Ma
Format:	Article
Language:	English
Published:	Elsevier 2022-09-01
Series:	Journal of Global Antimicrobial Resistance
Subjects:	Community-acquired pneumonia β-lactams Macrolides Fluoroquinolones Network meta-analysis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716522001138

Similar Items

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis
by: Sitong Liu, et al.
Published: (2019-05-01)

Comparing Several Treatments with Antibiotics for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Fusheng Bai, et al.
Published: (2021-06-01)

Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis
by: Khalid Eljaaly, et al.
Published: (2017-06-01)

Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis
by: Luis Felipe Reyes, et al.
Published: (2023-05-01)

Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence
by: Sellarès-Nadal J, et al.
Published: (2020-11-01)

Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial
by: Douwe F. Postma, et al.
Published: (2019-01-01)

Comparison of prognostic factors between bacteraemic and non-bacteraemic critically ill immunocompetent patients in community-acquired severe pneumococcal pneumonia: a STREPTOGENE sub-study
by: Hugo Bellut, et al.
Published: (2021-10-01)

Mycoplasma pneumoniae: Atypical Pathogen in Community Acquired Pneumonia
by: Abdul-Rahman Mamdouh Mohammad, et al.
Published: (2020-12-01)

Doxycycline vs. macrolides in combination with a β-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients
by: Raghad K. Aldhahri, et al.
Published: (2022-12-01)

EXPERIENCE OF RESPIRATORY FLUOROHINOLONUM LAEVOFLOXACINE APPLICATION («FLORACID®») IN PATIENTS WITH NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA
by: A.P. Rebrov, et al.
Published: (2007-09-01)

Macrolides in the modern therapy of community-acquired pneumonia in children
by: Yu. L. Mizernitskiy
Published: (2020-11-01)

Macrolide-resistant <it>Mycoplasma pneumoniae</it> in adolescents with community-acquired pneumonia
by: Miyashita Naoyuki, et al.
Published: (2012-05-01)

Evaluation of the Effect of Comorbidity on the Efficacy and Safety of β-Lactam Antibiotics in Patients with Community-Acquired Pneumonia
by: O. V. Muslimova, et al.
Published: (2022-07-01)

Mechanisms of antibiotic resistance in Haemophilus parainfluenzae
by: Regina E. Abotsi, et al.
Published: (2017-10-01)

Treatment of community-acquired pneumonia using the modern therapeutical guides
by: Škodrić-Trifunović Vesna, et al.
Published: (2006-01-01)

Potential for the use of macrolides in the antimicrobial therapy of severe community-acquired pneumonia in adults
by: Sinopalnikov A.I., et al.
Published: (2019-12-01)

Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters
by: Rein Jan Piso, et al.
Published: (2013-09-01)

PLACE OF RESPIRATORY FLUOROQUINOLONES IN THERAPY OF COMMUNITY ACQUIRED PNEUMONIA: FOCUS ON HIGH-DOSE LEVOFLOXACINE THERAPEUTIC REGIME
by: A. I. Sinopalnikov
Published: (2017-11-01)

Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis
by: Jong Gyun Ahn, et al.
Published: (2021-09-01)

Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy
by: Donald BJ, et al.
Published: (2017-12-01)

Novel β-lactam/β-lactamase inhibitor combinations versus alternative antibiotics in adults with hospital-acquired pneumonia or ventilator-associated pneumonia: an integrated analysis of three randomised controlled trials
by: Huamei Zhuang, et al.
Published: (2022-06-01)

The epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019–2020
by: Cheng-Yen Kuo, et al.
Published: (2022-08-01)

Macrolide-Resistant Mycoplasma pneumoniae in Humans, Ontario, Canada, 2010–2011
by: AliReza Eshaghi, et al.
Published: (2013-09-01)

Características clínicas y epidemiológicas de las neumonías adquiridas en la comunidad por Mycoplasma pneumoniae en una población española, 2010-2015
by: David Aguilera-Alonso, et al.
Published: (2019-07-01)

Macrolides and their role in the treatment of community-acquired pneumonia of various etiology
by: I. V. Leschenko, et al.
Published: (2015-12-01)

Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study
by: Davood Yadegarynia, et al.
Published: (2022-08-01)

Community-acquired pneumonia /
by: Suttorp, N. (Norbert), 1953-, et al.
Published: (2007)

Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial
by: Fernando G. Rubio, et al.

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
by: George D. Rodriguez, et al.
Published: (2023-07-01)

Dilemma of community-acquired pneumonia
by: Lamia H Shaaban
Published: (2019-01-01)

Cost-effectiveness analysis of empiric antibiotics in hospitalized community-acquired Pneumonia
by: Yeni Farida, et al.
Published: (2022-03-01)

Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
by: Xiwen Du, et al.
Published: (2021-10-01)

Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia
by: Mariana Lopes, et al.
Published: (2021-01-01)

Uncomplicated Urinary Tract Infections and Antibiotic Resistance—Epidemiological and Mechanistic Aspects
by: Bernd Wiedemann, et al.
Published: (2014-07-01)

Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review
by: Andrey A. Zaytsev, et al.
Published: (2023-09-01)

Features of laboratory indicators of severe community-acquired pneumonia
by: Pertzeva T.A., et al.
Published: (2017-06-01)

Psittacosis caused severe community-acquired pneumonia accompanied by acute hypoxic respiratory failure: a multicenter retrospective cohort study from China
by: Xiao Tang, et al.
Published: (2023-08-01)

Effect of 23S rRNA gene mutations in Mycoplasma pneumoniae on severity of communityacquired pneumonia in young adult patients treated at the Smolensk militar y hospital
by: Ivanova O.V., et al.
Published: (2020-12-01)

Oral vs. parenteral antibiotic therapy in adult patients with community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials
by: Ge-Ling Teng, et al.
Published: (2023-03-01)

chlamydia pneumoniae unfection in - patients with community acquired pneumonia in Iraq
by: hayfaa D. Salman
Published: (2009-01-01)